Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy
The longer survival of patients with Duchenne muscular dystrophy due to advances in clinical care has increased the incidence of Duchenne muscular dystrophy-associated cardiomyopathy, a nearly consistent feature in the third decade of life. A 26-year-old patient with Duchenne muscular dystrophy experienced severe acute heart failure triggered by pneumonia. Levosimendan was effective in improving heart function.
KeywordsDuchenne muscular dystrophy Levosimendan Acute heart failure
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
The authors assert that all procedures contributing to this work comply with the ethical standard of the relevant national guidelines on human experimentation (1988 Huriet Law and 2004 Public Health Policy Law) and with the Helsinki Declaration of 1975, as revised in 2008, and has been approved by the institutional committee Comité de Protection des Personnes Ile-de-France XI, Saint-Germain en Lay, France.
- 6.Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT (2006) Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 98(12):1641–1645CrossRefPubMedGoogle Scholar